Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 6, 2006 - Issue 5
Submit an article Journal homepage
414
Views
103
CrossRef citations to date
0
Altmetric
Review

Present and potential future issues in glioblastoma treatment

Florence Lefranc Clinical Research Fellow with the Fonds National de la Recherche Scientifique, Departments of Neurosurgery, Erasme University Hospital, Brussels, Belgium. [email protected]
,
Niloufar Sadeghi Departments of Radiology, Erasme University Hospital, Brussels, Belgium. [email protected]
,
Isabelle Camby Laboratory of Toxicology, Institute of Pharmacy, Free University of Brussels (U.L.B.), Brussels, Belgium. [email protected]
,
Thierry Metens Departments of Radiology, Erasme University Hospital, Brussels, Belgium. [email protected]
,
Olivier Dewitte Departments of Neurosurgery, Erasme University Hospital, Brussels, Belgium. [email protected]
&
Robert Kiss Director of Research with the Fonds National de la Recherche Scientifique, Laboratory of Toxicology, Institute of Pharmacy, Free University of Brussels (ULB), Brussels, Belgium. [email protected]
Pages 719-732 | Published online: 10 Jan 2014

References

  • Kleihues P, Cavenee WK. In: Pathology and Genetics Of Tumours Of The Nervous System. International Agency for Research on Cancer (IARC) and WHO Health Organisation. Oxford Press, Oxford, UK (2000).
  • Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer79, 2409–2413 (1997).
  • Basso U, Monfardini S, Brandes AA. Recommendations for the management of malignant gliomas in the elderly. Expert Rev. Anticancer Ther.3, 643–654 (2003).
  • Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J. Med.168, 114–120 (1998).
  • Gilbert MR, Loghin M. The treatment of malignant gliomas. Curr. Treat. Options Neurol.7, 293–303 (2005).
  • Leimgruber A, Ostermann S, Yeon EJ et al. Perfusion and diffusion mri of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int. J. Radiat. Oncol. Biol. Phys.64(3), 869–875 (2006).
  • Sugahara T, Korogi Y, Kochi M et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J. Magn. Reson. Imaging9, 53–60 (1999).
  • Nadal Desbarats L, Herlidou S, de Marco G et al. Differential MRI diagnosis between brain abscesses and necrotic or cystic brain tumors using the apparent diffusion coefficient and normalized diffusion-weighted images. Magn. Reson. Imaging21, 645–650 (2003).
  • Principi M, Italiani M, Guiducci A et al. Perfusion MRI in the evaluation of the relationship between tumour growth, necrosis and angiogenesis in glioblastomas and grade 1 meningiomas. Neuroradiology45, 205–211 (2003).
  • Law M, Yang S, Wang H et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am. J. Neuroradiol.24, 1989–1998 (2003).
  • De Witte O, Oulad Ben Taib N, Branle F, Rorive S, Brotchi J, Goldman S. Contribution of PET to the management of patients with low-grade glioma. Neurochirurgie50, 468–473 (2004).
  • Graves EE, Nelson SJ, Vigneron DB et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after γ-knife radiosurgery. AJNR Am. J. Neuroradiol.22, 613–624 (2001).
  • Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin. Nucl. Med.33, 148–162 (2003).
  • Vos MJ, Hoekstra OS, Barkhof F et al. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J. Clin. Oncol.21, 3559–3565 (2003).
  • Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
  • Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology54, 1886–1893 (2000).
  • Laws ER, Parney IF, Huang W et al. Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg.99, 467–473 (2003).
  • Hsieh JC, Lesniak MS. Surgical management of high-grade gliomas. Expert Rev. Neurother.5(6 Suppl.), S33–S39 (2005).
  • Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95, 190–198 (2001).
  • Chang SM, Parney IF, Huang W et al. Glioma Outcomes Project Investigators. Patterns of care for adults with newly diagnosed malignant glioma. JAMA.293, 557–564 (2005).
  • Jackson RJ, Fuller GN, Abi-Said D et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncology3, 193–200 (2001).
  • Pirotte B, Goldman S, Massager N et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J. Neurosurg.101, 476–483 (2004).
  • Keles GE, Berger MS. Advances in neurological technique in the current management of brain tumors. Semin. Oncol.31, 659–665 (2004).
  • Nimsky C, Ganslandt O, Kober H, Buchfelder M, Fahlbusch R. Intraoperative magnetic resonance imaging combined with neuronavigation: a new concept. Neurosurgery48, 1082–1091 (2001).
  • Kelly PJ. Technology in the resection of gliomas and the definition of madness. J. Neurosurg.101, 284–286 (2004).
  • Nabavi A, Black PM, Gering DT et al. Serial intraoperative magnetic resonance imaging of brain shift. Neurosurgery48, 787–798 (2001).
  • Strummer W, Reulen HJ, Novotny A, Stepp H, Tonn JC. Fluorescence-guided resections of malignant gliomas – an overview. Acta Neurochir. (Suppl.88), 9–12 (2003).
  • Lefranc F, Brotchi J, Kiss R. Present and future issues in the treatment of malignant gliomas, with a special emphasis on cell migration and the resistance of migrating glioma cells to apoptosis. J. Clin. Oncol.23, 2411–2422 (2005).
  • Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer3, 489–501 (2004).
  • Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology1, 44–51 (1999).
  • Benjamin R, Capparella J, Brown A. Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J.9, 82–90 (2003).
  • Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv. Anat. Pathol.10, 212–217 (2003).
  • Decaestecker C, Camby I, Gordower L, et al. Characterization of the astroglial versus the oligodendroglial origin of glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy. J. Neuropathol. Exp. Neurol.57, 791–802 (1998).
  • He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J. Neuropathol. Exp. Neurol.60, 863–871 (2001).
  • Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiother. Oncol.64, 259–273 (2002).
  • Fiveash JB, Spencer SA. Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J.9, 222–229 (2003).
  • Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int. J. Radiat. Oncol. Biol. Phys.60, 853–860 (2004).
  • Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90, 1473–1479 (1998).
  • Louis DN, Holland EC, Cairncross JG. Glioma classification. A molecular reappraisal. Am. J. Pathol.159, 779–786 (2001).
  • Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas. Int. J. Radiat. Oncol. Biol. Phys.18, 321 (1990).
  • Krishan A, Frei E. Morphological basis for the cytolytic effect of vinblastine and vincristine on cultured human leukemic lymphoblasts. Cancer Res.35, 497 (1975).
  • Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res.6, 2585–2597 (2000).
  • Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343, 1350–1354 (2000).
  • Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res.10, 1871–1874 (2004).
  • Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ.11, 448–457 (2004).
  • Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer4, 592–603 (2004).
  • Ogier-Denis E, Codogno P. Autophagy: a barrier or an adaptive response to cancer. Biochim. Biophys. Acta1603, 113–128 (2003).
  • Berens ME, Giese A. “…those left behind.” Biology and oncology of invasive glioma cells. Neoplasia1, 208–219 (1999).
  • Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol.21, 1624–1636 (2003).
  • Lefranc F, James S, Camby I et al. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthopic xenografts. J. Neurosurg.102, 706–714 (2005).
  • Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma: a review. Int. J. Oncol.28(5), 1021–1030 (2006).
  • Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology5, 79–88 (2003).
  • Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet359, 1011–1018 (2002).
  • Heimberger AB, Archer GE, McLendon RE et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res.6, 4148–4153 (2000).
  • Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol.65, 37–48 (2003).
  • Sampson JH, Akabani G, Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol.65, 27–35 (2003).
  • Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol.65, 3–13 (2003).
  • Kapoor GS, O’Rourke DM. Mitogenic signaling cascades in glial tumors. Neurosurgery52, 1425–1434 (2003).
  • Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol.13, 52–61 (2003).
  • Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res.62, 6764–6769 (2002).
  • Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res.62, 5749–5754 (2002).
  • Pfeffer MR, Levitt ML, Aderka D. Gefitinib in recurrent glioblastoma. J. Clin. Oncol.22, 2755–2756 (2004).
  • Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol.23, 9359–9368 (2005).
  • Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22, 133–142 (2004).
  • Prados M, Chang S, Burton E et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. Oncol.22, 99 (2003).
  • Raizer JJ, Abrey LE, Wen P et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant glioma not on EIAEDs. J. Clin. Oncol.22(Suppl.) 107 (2004).
  • Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
  • Goudar RK, Shi Q, Hjelmeland MD et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther.4, 101–112 (2005).
  • Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer4, 335–348 (2004).
  • McCormick F. Survival pathways meet their end. Nature428, 267–269 (2004).
  • Sekulié A, Hudson CC, Homme JL et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res.60, 3504–3513 (2000).
  • Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North Central Cancer Treatment Group Study. J. Clin. Oncol.23, 5294–5304 (2005).
  • Hidalgo H, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst.93, 178–193 (2001).
  • Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol.20, 1383–1388 (2002).
  • Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat. Res.117, 307–336 (2004).
  • Lamszus K, Heese O, Westphal M. Angiogenesis-related growth factors in brain tumors. Cancer Treat. Res.117, 169–190 (2004).
  • Morabito A, Fanelli M, Carillio G, Gattuso D, Samiento R, Gasparini G. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol. Rep.11, 93–95 (2004).
  • Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-oncology7, 369 (2005).
  • Caruso DA, Orme LM, Neale AM et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology6, 236–246 (2004).
  • Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res.64, 4973–4979 (2004).
  • Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br. J. Cancer89, 1172–1179 (2003).
  • Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin. J. Immunother.27, 452–459 (2004).
  • Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res.11, 5515–5525 (2005).
  • Kanzawa T, Ito H, Kondo Y, Kondo S. Current and future gene therapy for malignant gliomas. J. Biomed. Biotechnol.2003, 25–34 (2003).
  • Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther.4, 1103–1113 (2004).

Website

  • www.clinicaltrials.gov/ct/search;jsessionid=854243dc237d32c8bed356a7adb0f791?term=glioblastoma

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.